Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Bellmunt Molins, Joaquin
Item TypeName
Academic Article Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
Academic Article A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Academic Article ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
Concept Immunotherapy, Active
Concept Immunotherapy
Academic Article A multinational phase II trial of bevacizumab with low-dose interferon-a2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
Academic Article Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Academic Article New agents for prostate cancer.
Academic Article MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Academic Article Cancer immunotherapy: new applications in urologic oncology.
Academic Article Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Academic Article A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Academic Article Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Academic Article From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis.
Academic Article Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Academic Article Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Academic Article Antiangiogenesis to curb urothelial cancer.
Academic Article Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Academic Article Avelumab for the treatment of urothelial cancer.
Academic Article Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
Academic Article Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes.
Academic Article Treatment of Metastatic Urothelial Cancer in 2018.
Academic Article Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.
Search Criteria
  • Immunotherapy
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.